New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Tvardi Therapeutics, Inc. (TVRD) news

Stories the last two months, newest first

  1. Other ·

    Tvardi receives FDA feedback supporting TTI-109 development

    Tvardi received constructive FDA pre-IND feedback on TTI-109, supporting its proposed Phase 2 development in ulcerative colitis and potentially Crohn’s disease. The company plans to submit an IND in 2027; Phase 2 initiation depends on FDA clearance and additional funding. New analysis of Phase 1 exposure data suggests proposed doses may sustain STAT3 inhibition while minimally affecting STAT1 and STAT5, though selectivity and safety benefits remain unproven in patients.

    Reported by Globe Newswire

  2. Results ·

    Tvardi reports a third-quarter loss of $6.1 million

    Tvardi reported third-quarter 2026 results, with a net loss of $6.1 million and $22.3 million in cash expected to fund planned operations into Q3 2027. The company is preparing to advance TTI-109 into ulcerative colitis trials in 2027, subject to IND clearance and additional funding, following positive Phase 1 findings. Topline data from the TTI-101 HCC study is expected in early Q1 2027.

    Reported by 2: GlobeNewswire · Associated Press

More headlines